In MS, DHA and EPA were observed to upregulate M2-specific markers (TGFβ, Arg1, IL-5, and CD206) while downregulating inflammatory cytokines (TNF-α and IL-6) and M1-specific markers (CCL5, CD14, IL-1, and iNOS). This evidence concerns the gene MRC1 and myeloid sarcoma.